Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor
about
Novel Techniques for Ex Vivo Expansion of Cord Blood: Clinical TrialsAlternative Donor Transplantation for Acute Myeloid LeukemiaAlternative Donor Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid LeukemiaMarrow damage and hematopoietic recovery following allogeneic bone marrow transplantation for acute leukemias: Effect of radiation dose and conditioning regimen.Thymocyte expansion and maturation: crosstalk of CD44v6 on thymocytes and panCD44 on stroma cells.From patient centered risk factors to comprehensive prognostic models: a suggested framework for outcome prediction in umbilical cord blood transplantation.Engineering cord blood to improve engraftment after cord blood transplant.Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality.Reduced-intensity hematopoietic cell transplantation in older patients with AML/MDS: umbilical cord blood is a feasible option for patients without HLA-matched sibling donorsCosts of pediatric allogeneic hematopoietic-cell transplantation.Haploidentical vs cord blood transplantation for adults with acute myelogenous leukemia.Comorbidity-age index: a clinical measure of biologic age before allogeneic hematopoietic cell transplantation.Suberoylanilide hydroxamic acid induces hypersensitivity to radiation therapy in acute myelogenous leukemia cells expressing constitutively active FLT3 mutants.Optimal HLA matching in hematopoietic cell transplantation.Reduced intensity conditioning allogeneic hematopoietic cell transplantation for adult acute myeloid leukemia in complete remission - a review from the Acute Leukemia Working Party of the EBMT.Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research StudyCurrent status of allogeneic hematopoietic cell transplantation for MDS.Reduced intensity allogeneic haematopoietic cell transplantation for chronic lymphocytic leukaemia: related donor and umbilical cord allografting.Promising progression-free survival for patients low and intermediate grade lymphoid malignancies after nonmyeloablative umbilical cord blood transplantation.Transplantation of human umbilical cord blood-derived mesenchymal stem cells or their conditioned medium prevents bone loss in ovariectomized nude mice.How I assess comorbidities before hematopoietic cell transplantationAllogeneic hematopoietic cell transplantation for myelodysplastic syndrome: the past decade.Unrelated donor umbilical cord blood transplantation for the treatment of hematologic malignanciesThe evolution of hematopoietic SCT in myelodysplastic syndrome.Alternative haematopoietic stem cell sources for transplantation: place of umbilical cord blood.Future of cord blood for oncology uses.Reduced-intensity conditioning and umbilical cord blood transplantation in adults.Umbilical cord blood: biology and transplantation.An overview of the progress on double umbilical cord blood transplantation.Advances in conditioning regimens for older adults undergoing allogeneic stem cell transplantation to treat hematologic malignancies.Alternative novel therapies for the treatment of elderly acute myeloid leukemia patients.Alternative donor transplantation--"mixing and matching": the role of combined cord blood and haplo-identical donor transplantation (haplo-cord SCT) as a treatment strategy for patients lacking standard donors?Quantifying the survival benefit for allogeneic hematopoietic stem cell transplantation in relapsed acute myelogenous leukemiaAnalysis of 120 pediatric patients with nonmalignant disorders transplanted using unrelated plasma-depleted or -reduced cord blood.Cord blood transplants supported by co-infusion of mobilized hematopoietic stem cells from a third-party donor.Unrelated cord blood transplantation in pediatric patients: a report from Saudi Arabia.Hematopoietic stem cell transplant following remission induction chemotherapy including gemtuzumab ozogamicin is a feasible and effective treatment option in elderly patients with acute myeloid leukemia.Clinical T Cell Receptor Repertoire Deep Sequencing and Analysis: An Application to Monitor Immune Reconstitution Following Cord Blood Transplantation
P2860
Q26772216-DCEEFBCD-30C4-4E35-89BE-33E57F5C410FQ26799456-59FEEFE4-6213-49C1-AF72-00C6AFB912CAQ28080943-FC00F2C8-F9B7-4849-BD1C-DAC38413A131Q33428284-0C228510-5ABF-4BAE-907C-72F9C8EF19DFQ33507242-5CACA380-71B4-4DEC-93A5-C52AD48BDA09Q33766984-5470E8ED-0034-4BEB-A944-6CA6F8208D32Q33766995-ACAC7ED2-C461-4B5F-8517-CDFC859F5D90Q33886907-361E7AD2-7C9C-4252-951F-CA2B0709B47AQ33937055-A196A1EF-72E1-444F-ABA1-2A0BD0989CFDQ33953319-651EE562-86FB-46FB-AE63-8A01CBDC9439Q34232835-23D2EC2C-8B8F-43D7-8244-14282C471BAEQ34260505-8A663819-8AE7-4704-ADEA-F1FAD44FFDDFQ35075792-271F91CF-36E4-4963-9C77-35B07ED8F99AQ35237720-CB28DA5E-43D5-4FCB-81B8-CB60C5217015Q35800814-43096647-FE81-4B8C-A1F8-F55D3B3985FCQ35882830-46816A11-AB43-43BB-BEAC-6E1B61B6BC58Q36063049-91A9A768-F299-4090-A35C-CC9B7C114E55Q36092009-1686801B-EBE3-456F-8514-DB0546036FC2Q36092021-48306CDB-AFCE-47C4-89DF-A5725C6A6937Q36600189-6CD0F5AD-E2EE-40E5-AD14-D76D0F8C3A01Q36761518-72984FC0-6B28-4AEC-9BF3-8BBE3D1F422DQ36811828-B583E2B6-7DE4-4F57-B86B-AEA505057244Q36995771-0596B9C9-2920-4059-9601-B53C40E6D8FEQ37404489-1B60694F-3004-4F89-89BB-425F3D2B46BDQ37435417-A4617532-A2F7-4A8C-8F9F-AF8F4A292324Q37607977-017687C3-2E0E-419A-AA7D-AFC25B88375AQ37607984-C17F00F0-45FF-439B-B3BD-09ACA5C4E837Q37810269-28057032-190E-401B-8FCE-4A16C70DBEAEQ37872506-BB2E57B6-F38F-43BE-9702-6E22171790E8Q38095833-FB29F4D9-FBC0-46B4-B519-F7FF1CE1A58CQ38161965-8E3F7545-E7CA-4518-AD73-ADA3B6DAAF49Q38350274-4CE483CF-E5A3-4B53-A1D3-A4D80CEC7661Q41044948-7B252FE8-C28B-4C97-93FD-F4ADD4A22870Q43782772-608ADF77-55F2-4D3E-A441-28ABC021D641Q44885226-AB7C0191-B97E-4432-BB3E-29CE0DFB96ACQ50156537-D436119E-2EE3-4019-9607-798BBA6F8C2CQ53210874-A111179A-AF18-4BF9-8ECA-33A906DB28B1Q59129883-886941D0-9C47-47A3-A9C9-9BF033D777E6
P2860
Reduced-intensity allogeneic transplant in patients older than 55 years: unrelated umbilical cord blood is safe and effective for patients without a matched related donor
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on March 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Reduced-intensity allogeneic t ...... ithout a matched related donor
@en
Reduced-intensity allogeneic t ...... thout a matched related donor.
@nl
type
label
Reduced-intensity allogeneic t ...... ithout a matched related donor
@en
Reduced-intensity allogeneic t ...... thout a matched related donor.
@nl
prefLabel
Reduced-intensity allogeneic t ...... ithout a matched related donor
@en
Reduced-intensity allogeneic t ...... thout a matched related donor.
@nl
P2093
P2860
P1476
Reduced-intensity allogeneic t ...... ithout a matched related donor
@en
P2093
Arne Slungaard
Avis J Thomas
Claudio G Brunstein
Dan S Kaufman
Daniel J Weisdorf
John E Wagner
Linda J Burns
Marcie Tomblyn
Mukta Arora
Navneet S Majhail
P2860
P304
P356
10.1016/J.BBMT.2007.12.488
P577
2008-03-01T00:00:00Z